These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1139228)

  • 21. Use of angiotensin antagonists in experimental and human renovascular hypertension.
    Maxwell MH
    Adv Nephrol Necker Hosp; 1979; 8():297-319. PubMed ID: 115245
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical implications of renin in the hypertensive patient.
    Brunner HR; Gavras H
    JAMA; 1975 Sep; 233(10):1091-3. PubMed ID: 1174160
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiotensin inhibitors for hypertension.
    Gavras H; Gavras I; Brunner HR
    Compr Ther; 1980 May; 6(5):14-8. PubMed ID: 6155240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of an angiotensin blocker, sarcosyl1-alanyl8-angiotensin II (P113) on two kidney hypertension in the rat.
    Macdonald GJ; Boyd GW; Peart WS
    Clin Exp Pharmacol Physiol; 1975; Suppl 2():89-91. PubMed ID: 1183095
    [No Abstract]   [Full Text] [Related]  

  • 25. Angiotensin as a renal, adrenal, and cardiovascular hormone: responses to saralasin in normal man and in essential and secondary hypertension.
    Hollenberg NK; Williams GH
    Kidney Int Suppl; 1979 Mar; (9):S29-35. PubMed ID: 384070
    [No Abstract]   [Full Text] [Related]  

  • 26. [The effect of an angiotensin antagonist on blood pressure, renin and aldosterone secretion and its pathogenetic importance].
    Beckerhoff R
    Schweiz Med Wochenschr Suppl; 1978; (7):1-24. PubMed ID: 349683
    [No Abstract]   [Full Text] [Related]  

  • 27. [Arterial hypertension and maintenance hemodialysis: effects of specific inhibition of angiotensin II by saralasin acetate].
    Mimran A; Deschodt G; Shaldon S; Barjon P; Mion C
    Arch Mal Coeur Vaiss; 1978 Jul; 71 Spec No():19-24. PubMed ID: 101176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grand rounds: diagnosis and management of renovascular hypertension.
    Carey RM
    Va Med; 1979 Nov; 106(11):809-18. PubMed ID: 388907
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical usefulness of saralasin in human hypertension (author's transl)].
    Fouchard M; Bichara M; Grüfeld JP; Barbanel C; Meyer P; Funck-Brentano JL
    Nouv Presse Med; 1978 Feb; 7(7):539-43. PubMed ID: 643579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged treatment of high-renin hypertension with a converting enzyme inhibitor.
    Vandenburg MJ; Sharman VL; Marsh FP; Rucinska EJ
    Br Med J; 1978 Sep; 2(6141):866. PubMed ID: 709099
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug suppression of the angiotensin system in congestive heart failure.
    Sullivan JM
    Annu Rev Med; 1983; 34():169-77. PubMed ID: 6190432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saralasin infusion in renovascular and essential hypertension.
    Thien T; Hoefnagels WH
    Neth J Med; 1980; 23(2):68-73. PubMed ID: 6990282
    [No Abstract]   [Full Text] [Related]  

  • 34. [Variable action of central and peripheral angiotensin II blockade in genetic hypertension in rats].
    Mann JF; Phillips MI; Dietz R; Haebara H; Lüth JB; Ganten D
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():189-90. PubMed ID: 613564
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of the angiotensin antagonist saralasin on hemodynamics in hypertensive non-uraemic chronic renal disease.
    Brod J; Bahlmann J; Cachovan M; Hubrich W; Pretschner D
    Nephron; 1980; 25(4):167-72. PubMed ID: 6990284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin blockade in coarctation of the aorta.
    Ribeiro AB; Krakoff LR
    N Engl J Med; 1976 Jul; 295(3):148-50. PubMed ID: 1272332
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of saralasin in end-stage renal disease.
    Fadem SZ; Lifschitz MD
    Kidney Int Suppl; 1979 Mar; (9):S93-100. PubMed ID: 289869
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
    Bing RF; Russell GI; Swales JD; Thurston H
    J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The renin system in essential, renovascular and adrenocortical hypertension: an overview.
    Laragh JH
    Adv Nephrol Necker Hosp; 1977; 7():157-89. PubMed ID: 96672
    [No Abstract]   [Full Text] [Related]  

  • 40. [Blood pressure behavior following 1-sar-8-ala-angiotensin II (saralasin) in essential and renovascular hypertension].
    Rosenthal J; Franz HE
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1305-7. PubMed ID: 1029984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.